| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514556000 | Inner quaternary ammonium salt (e.g., betaine, etc.) | 38 |
| 20080234373 | Compound Useful For the Prevention and Treatment of Left Ventricular Hypertrophy in Dialysed Patients - Is described the use of propionyl L-carnitine, or a pharmaceutical salt thereof, for preparing a medicament for the prevention and/or treatment of left ventricular hypertrophy in ESRD or dialysed patients. | 09-25-2008 |
| 20080287539 | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause - L-carnitine, propionyl L-carnitine and/or acetyl L-carnitine are used to prevent or treat disorders of male andropause caused by ageing or by chemical or surgical castration. | 11-20-2008 |
| 20090054521 | ZWITTERIONIC COMPOUNDS AND USE THEREOF - The present invention covers zwitterionic, non-surface-active compounds in the form of carboxymethylated, short-chain dialkylaminoalkylamides and use thereof as therapeutic agent. | 02-26-2009 |
| 20090062388 | Use of acetyl L-carnitine for the preparation of a medication for the preventive therapy for pain - The invention relates to the use of the acetyl L-carnitine, or a pharmaceutically acceptable salt thereof for the preparation of a medication for the preventive therapy for pain. | 03-05-2009 |
| 20090137670 | Amino Acid Compounds - Carnitine and Taurine Compounds are described. The Carnitine Compound comprises Carnitine and one of a Nitrate and a Nitrite. The Taurine Compound comprises Taurine and one of a Nitrate and a Nitrite. | 05-28-2009 |
| 20090281183 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME - L-carnitine calcium fumarate and its preparation and applications are disclosed in the present invention. Having good water solubility as well as better and stronger nutritious and treating functions than the corresponding inner salts, the L-carnitine calcium fumarate as proposed having the advantages of being non-hygroscopic, stable in chemical property, and suitable for oral administration. A preparing method is as follow: fumaric acid is suspended in water and calcium base is added. The resulting mixture is heated up to 70˜90° C. and kept under stirring for 2˜8 hours, and then concentrated under reduced pressure. The resulting dried substance is added into ethanol, and the mixture is vigorously stirred. The inner salt of L-carnitine is added, and the mixture is reacted for 1-6 hours at 60˜70° C. and then cooled for 2˜8 hours. L-carnitine calcium fumarate is obtained by filtration. | 11-12-2009 |
| 20100093859 | Compositions and Methods For Enhancing Neurological Development - Compositions and methods useful to enhance neurologic development of a growing animal are disclosed. | 04-15-2010 |
| 20100210724 | Method for modifying the properties of an aqueous suspension - A method for modifying the properties of a suspension of solid or liquid particles in an aqueous medium, includes the step of adding to the suspension or to the aqueous medium a polymer prepared by inverse emulsion polymerization of monomers A | 08-19-2010 |
| 20100210725 | COPOLYMER-GRAFTED POLYOLEFIN SUBSTRATE HAVING ANTIMICROBIAL PROPERTIES AND METHOD FOR GRAFTING - A method for grafting a copolymer onto a polyolefin substrate includes the following steps:
| 08-19-2010 |
| 20100234459 | MEDICALL USE OF 3-(2,2,2,-TRIMETHYLYHDRAZINIUM) PROPIONATE HDROGEN FUMARATE AND DIHYDROGEN PHOSEPHATE - Novel medical use of 3-(2,2,2-trimethylhydrazinium) propionate salts for the manufacture of a medicament for prevention and therapy of atherosclerosis. | 09-16-2010 |
| 20100273880 | STORAGE-STABLE AQUEOUS COMPOSITION COMPRISING A MAGNESIUM COMPOUND AND L-CARNITINE - The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting muscle structure, and its use as food supplement or in the veterinary sector as animal feed additive, in particular for horses, poultry, pigeons, pigs, cattle, sheep and camels. | 10-28-2010 |
| 20110021632 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION - The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system. | 01-27-2011 |
| 20110086917 | USE OF L-CARNITINE FOR THE TREATMENT OF CARDIOVASCULAR DIESASES - The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally. | 04-14-2011 |
| 20110190394 | CARNITINE GRANULATE AND METHODS FOR ITS PRODUCTION - Subject of the invention is a method for the production of a carnitine granulate, which includes the steps of
| 08-04-2011 |
| 20110196036 | USE OF BETAINE - The present invention relates to use of betaine for protecting skin from biological irritation. The invention also relates to the use of betaine as a protecting agent in a cosmetic and/or toiletry preparation. The invention further relates to a method of protecting skin from biological irritation. | 08-11-2011 |
| 20120101160 | Use of chemical chaperones to treat glaucoma caused by misfolded or misprocessed proteins - The present invention provides methods for treating glaucoma by administering compounds capable of stabilizing misprocessed or misfolded proteins that are responsible for the condition. | 04-26-2012 |
| 20120172435 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA - The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well. | 07-05-2012 |
| 20120172436 | Liver Regeneration Accelerator Comprising Betaine - The present invention relates to betaine or a composition comprising the same for accelerating liver regeneration, more particularly, a therapeutic pharmaceutical composition comprising betaine represented by formula 1 as an active ingredient for promoting the recovery of injured or resected liver to the normal liver. The most effective treatment for chronic liver disease, particularly in the terminal stage, is hepatectomy and liver transplantation. In Living Donor Liver Transplantation (LDLT) that has been increasing since 1990, rapid regeneration of liver tissues is essential for both donor and recipient to inhibit complications and thus for the success of the treatment. Betaine accelerates the recovery and growth of injured liver to the normal liver, so that it can be effectively used for the successful LDLT or therapeutic hepatectomy. | 07-05-2012 |
| 20120214870 | METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC FATIGUE SYNDROME - Methods for the diagnosis and treatment of chronic fatigue syndrome (CFS) are disclosed based upon the finding that particular individual acylcarnitines are present in modified concentrations (ie decreased or increased concentrations) in CFS patients compared to healthy control subjects. In one form of the invention, a diagnostic method comprises determining a concentration of at least one individual acylcarnitine compound (eg oleyl-L-carnitine and linoleyl-L-carnitine) in a body sample from a test subject and comparing the concentration to a reference concentration, wherein a difference in the concentration of the at least one individual acylcarnitine from the test subject compared to the reference concentration is indicative of CFS. In another form of the invention, a method of treating CFS is provided which comprises administering an effective amount of a supplement comprising: at least one acylcarnitine compound selected from short-chain, medium-chain and long-chain acylcarnitines, L-carnitine (or an acylcarnitine that may be converted within a subject to L-carnitine) in combination with at least one fatty acid selected from short-chain, medium-chain and long-chain fatty acids, or at least one acylcarnitine in combination with at least one fatty acid selected from short-chain, medium-chain and long-chain fatty acids. | 08-23-2012 |
| 20120220656 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE - New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease. | 08-30-2012 |
| 20120329872 | Ready-To-Eat Feed For Domestic Pets - A new finished feed for domestic pets is proposed, containing at least one guanidinoacetic acid component as the active component with regard to nutritional physiology. The new finished feed which preferably has a water content of >8% by weight, can be produced in an extremely economical manner, wherein the main component has a significantly higher stability during passage through the gastrointestinal tract and is therefore only converted into creative under physiological conditions. For this reason the guanidinoacetic acid is also utilized to a high degree by the target group which is in particular cats and dogs. | 12-27-2012 |
| 20130005810 | ORGANIC UNCOUPLING AGENTS - The present invention relates to a method for controlling the growth of bacterial biomass in an aqueous system, including adding to the aqueous system or contacting the aqueous system, with an efficient amount of an uncoupling agent selected from vanillin, pentaerythritol and a betaine of general formula (1): (R) | 01-03-2013 |
| 20130041028 | METHODS OF USING (1S,3S)-3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID - (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril). | 02-14-2013 |
| 20130079407 | ANTIMICROBIAL COMPOSITION AND METHODS FOR USING SAME - An aqueous composition adapted to kill bacteria in both planktonic and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The composition, which is slightly to moderately acidic, includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. The composition can be applied directly to a site of bacterial growth. Even when the bacteria is in biofilm form, the surfactant component(s) begin to kill the bacteria before the macro-molecular matrix is removed or dislodged from the site. | 03-28-2013 |
| 20130096195 | THERAPEUTIC TREATMENT - The invention describes the use of betaine alone for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a medicament provided for treating a patient suffering from an intermittent claudication caused by peripheral circulatory disorders such as arteriosclerosis obliterans or by thromboangiitis obliterans. | 04-18-2013 |
| 20130172414 | PHARMACEUTICAL COMPOSITION COMPRISING LEVOCARNITINE AND DOBESILATE - A pharmaceutical composition comprising levocarnitine and dobesilate is provided. Also provided are a method for regulating the level of serum creatinine and/or blood urea nitrogen and a method for treating and/or preventing the diseases influencing renal function, for example, including but not limiting to various primary, secondary nephritis, renal lesions, renal insufficiency, nephritic syndrome, even renal failure, uremia, as well as the complications induced by the diseases and/or disorders influencing renal function for example, such as cardiovascular diseases, diabetes and the like. | 07-04-2013 |
| 20130190398 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES - Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery. | 07-25-2013 |
| 20130203848 | COMPOUNDS USEFUL FOR INCREASING NEUROGENESIS IN NEURAL TISSUE - The invention, described herein, is directed to the use of acetyl. L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in winch said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition. | 08-08-2013 |
| 20140024711 | LOW ALCOHOL ANTIMICROBIAL CLEANSING COMPOSITION - An antimicrobial cleansing composition including (a) 20 to less than 60 wt. % of at least one alcohol selected from ethanol and propanol; (b) 0.5 to 10 wt. % of a surfactant selected from sulfate salt surfactants and amphoteric surfactants. The composition shows effective cleansing and antimicrobial properties. Hence, using this composition, it will no longer be required to provide in hospitals two separate dispensers one for foam soap and one for antimicrobial alcohol-based composition. The antimicrobial cleansing composition can be used for making foam. Also, a dispenser contains the above antimicrobial cleansing composition. | 01-23-2014 |
| 20140024712 | ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OF PAINFUL PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES - Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day. | 01-23-2014 |
| 20140045939 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES - Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery. | 02-13-2014 |
| 20140080907 | LIVER REGENERATION ACCELERATOR COMPRISING BETAINE - The present invention relates to betaine or a composition comprising the same for accelerating liver regeneration, more particularly, a therapeutic pharmaceutical composition comprising betaine as an active ingredient for promoting the recovery of injured or resected liver to the normal liver. The most effective treatment for chronic liver disease, particularly in the terminal stage, is hepatectomy and liver transplantation. In Living Donor Liver Transplantation (LDLT) that has been increasing since 1990, rapid regeneration of liver tissues is essential for both donor and recipient to inhibit complications and thus for the success of the treatment. Betaine accelerates the recovery and growth of injured liver to the normal liver, so that it can be effectively used for the successful LDLT or therapeutic hepatectomy. | 03-20-2014 |
| 20140107201 | Use of L-Carnitine, Salts and Derivatives Thereof for Reducing or Preventing Fatigue and Improving Cognitive Function - The invention relates to the use of L-carnitine, a salt of L-carnitine, a derivative of L-carnitine and/or salt of a derivative of L-carnitine, as well as respective methods and compositions, for reducing or preventing fatigue and/or for improving cognitive function in an animal. The animal is preferably a healthy individual and the use is preferably a non-therapeutic use. | 04-17-2014 |
| 20140107202 | 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease - 4-[(Haloalkyl)(dimethyl)ammonio]butanoates of formula | 04-17-2014 |
| 20150045432 | DIETARY SUPPLEMENT COMPRISING AMINO ACIDS IN A PALATABLE LIQUID FORMULATION THAT PROMOTES RESTFUL SLEEP, RECOVERY FROM STRESS AND EXERCISE AND STRENGTHENS THE IMMUNE SYSTEM - A palatable, single serving dietary supplement of amino acids that may be taken as a nutritional aid to improve health and well-being by promoting higher quality sleep, enhancing repair of muscular tissue after strenuous exercise in part through boosting the natural production of human growth hormone, enhancing the immune system, improve gut barrier function, aiding in responses to upper respiratory viral pathogens, reversing side effects from the over use of nutritional energy drinks with stimulants and simple sugars and reverse the side effects of excess signaling through the cortisol pathway resulting from chronic environmental stress. | 02-12-2015 |
| 20160076065 | GENERATION OF ACYL AMINO ACIDS - Engineered polypeptides useful in synthesizing acyl amino acids are provided. Also provided are methods of making acyl amino acids using engineered polypeptides. | 03-17-2016 |
| 20160137589 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE - New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease. | 05-19-2016 |
| 20180021282 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | 01-25-2018 |
